Our data provide a strong rationale for clinical studies aimed to prospectively optimize the integration of NGS in the clinical management of Ph+ leukemia patients and lay the foundations for the revision of the ELN recommendations for BCR-ABL1 KD mutations analysis in CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.